Core Points - The company has announced the first unlock date and listing of its restricted stock incentive plan for 2023, with 190,000 shares set to be listed on September 4, 2025 [1][7] - The stock incentive plan has undergone multiple meetings and approvals, with independent opinions from directors and verification from the supervisory board [2][4] - The first unlock period for the reserved stock is set to expire on September 3, 2025, with specific performance conditions that must be met for the unlock to occur [5][6] Implementation of the Incentive Plan - The incentive plan has been approved through three meetings, with relevant proposals and independent opinions documented [2][4] - The company completed the registration of the first grant of restricted stock on September 21, 2023, awarding 2.49 million shares to 21 incentive recipients [2][3] - The reserved stock grant was registered on September 4, 2024, with 530,000 shares awarded to 13 recipients [3][4] Unlock Conditions and Performance Metrics - The first unlock conditions for the reserved stock require the company to achieve a net profit growth rate of at least 30% for 2024, based on 2022 figures [5][6] - Individual performance assessments will determine the unlock ratio for each recipient, with a total of 11 recipients meeting the conditions for unlock [6][7] - The total number of shares eligible for unlock is 190,000, representing 0.12% of the company's total share capital [7][8] Changes in Share Capital Structure - Following the unlock, the number of restricted shares will decrease from 2,119,000 to 1,929,000, while the number of unrestricted shares will increase from 157,237,477 to 157,427,477 [8] - The total share capital remains unchanged at 159,356,477 shares [8] Legal Compliance - The company has confirmed that all procedures related to the unlock of the reserved stock comply with relevant regulations and internal policies [8][9]
康辰药业: 康辰药业关于公司2023年限制性股票激励计划预留授予第一个限售期解除限售暨上市公告